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Demands for access to new therapies: are there
alternatives to accelerated access?
Patients deserve timely access to new therapies, but the rhetoric surrounding accelerated access
impedes rational policy making, argue Jessica Pace and colleagues
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It is almost impossible to turn on the television or open a
newspaper without hearing about the “miraculous” benefits of
the latest medicines. The targeted cancer therapy idelalisib, for
example, was touted as a revolutionary treatment that would
“melt away” your cancer,1 while the new leukaemia drug
venetoclax has been described as being so innocuous that it is
“like taking Panadol [paracetamol].”2 While much of this
rhetoric centres on cancer medicines, new treatments for other
chronic and life threatening conditions such as diabetes,3 cystic
fibrosis,4 and Duchenne muscular dystrophy5 are also described
as miracle cures.
The mass media is replete with stories of terminally ill patients
who have been given a second chance by these new miracle
drugs. However, alongside such stories of triumph are darker
stories—of patients having access to these life saving drugs
denied or compromised by excessively conservative regulators
or cost conscious public or private insurers (payers). Headlines
over the past few years include “Aussie patients denied funding
for 30 life-saving drugs,”6 “Dying mum fights for life-prolonging
drugs the NHS won’t fund due to cost,”7 and “Company denies
drug to dying child.”8
This rhetoric is indicative of an increasingly pervasive social
expectation, which we refer to as the access imperative. By this
we mean the view that patients with severe or life threatening
diseases should not have to wait (as long as they do) for
regulatory approval or formal subsidy before they can access
medicines. This access imperative seems to be gaining in
strength, leading to numerous recent inquiries into the adequacy
of existing regulatory and reimbursement systems including in
the UK and Australia,9 10 and calls to expedite access to
promising new treatments.
Politicians across the political divide seemingly accept the need
for faster access as truth. For example, US President Donald
Trump recently labelled the US Food and Drug Administration’s
(FDA) regulatory approval processes “slow and burdensome”
and vowed to deregulate the drug industry,11 while Obama’s
vice president, Joe Biden, committed to speeding up the approval
of promising new cancer drug combinations.12 In countries with
publicly funded insurance programmes, politicians appeal to
voters by promising to provide funding for medicines that have
been rejected by payers. For example, New Zealand’s opposition
Labour party committed to funding pembrolizumab for
melanoma after it was rejected by that country’s public payer.13
The drug industry and industry funded consumer groups across
the globe also promote faster access, encouraging patients to
demand access to timely and affordable medicines,14 and
advocate for the right to try experimental therapies without the
usual regulatory oversight.15
Global responses to demands for faster
access
In response to this pressure, many countries have introduced
formal programmes that provide earlier access to medicines,
targeting both regulatory and reimbursement processes. Some
of these accelerated access processes are relatively
uncontroversial because they simply improve the efficiency of
current decision making processes—for example, Europe, Japan,
the US, and Canada require regulatory bodies to prioritise
applications for marketing approval for drugs deemed to be
potentially life saving or a significant improvement over
currently available treatments for serious conditions.16-19 Others,
however, are more problematic, as they suspend or erode current
standards of safety, efficacy, or cost effectiveness. Numerous
jurisdictions have introduced systems that allow for provisional
approval of medicines on the basis of less complete data (such
as surrogate markers) on the condition that post-marketing
studies are done to resolve any uncertainties about safety or
clinical effectiveness.20-23 Many countries also allow individual
patients to apply to regulators for use of unregistered medicines
through special access schemes or early access programmes.24-26
Several “managed entry” or “coverage with evidence
development” schemes have also been established for therapies
that have been approved by regulators but not (yet) funded.
These schemes allow for funding of a therapy at a price justified
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by the evidence available at the time a decision is made, with
ongoing coverage—and final price—decided after the
accumulation of data from clinical trials or “real world” use.27-30
Formal programmes to fund therapies not deemed to be cost
effective by health technology assessment agencies (such as the
UK’s recently reconstituted Cancer Drugs Fund31 and Australia’s
Life-Saving Drugs Program32) have also been established. These
formal schemes exist alongside “compassionate access” or
“individual patient use” mechanisms, in which drug companies
fully or partly subsidise medicines that have not been subsidised
by public or private insurers.33
Such initiatives are not unique to the developed world.
Programmes were introduced to facilitate rapid access to
unapproved treatments during the recent Ebola virus epidemic
in west Africa after a World Health Organization panel
concluded that “it would be acceptable on both ethical and
evidential grounds to use as potential treatments or for
prevention unregistered interventions that have shown promising
results in the laboratory and in animal models but have not yet
been evaluated for safety and efficacy in humans.” 34
Effects of accelerated access
Good arguments exist for accelerating access to medicines.
Patients in desperate situations—such as those with life
threatening illness or rare diseases for which there is no available
treatment—should have timely access to potentially beneficial
therapies and be provided with hope of a cure.33 It is asserted
that it is up to these patients and their physicians, not regulators,
to determine when it is reasonable to try a therapy.35 In addition,
many people believe that particular groups of patients, such as
those with rare diseases, are disadvantaged because of the
difficulties of conducting clinical trials in small patient
populations and demonstrating cost effectiveness when drug
companies need to charge more to recoup their investment.36
Existing regulatory and subsidisation processes may indeed be
too slow to meet the needs of patients with limited life
expectancy. For instance, a recent analysis found that average
approval times of six major regulators ranged from 304 days
for the US FDA to 511 days for Swissmedic.37 Assessment by
public and private insurers (payers) can further increase the time
to access for more expensive medicines because of
affordability.33
Rigid adherence to inflexible standards for safety, efficacy, or
cost effectiveness (such as an emphasis on large phase III
randomised controlled trials) may also prevent timely access to
new therapies. Many drugs that were initially approved using
accelerated pathways have subsequently become part of standard
care, lending credence to the view that we need to modernise
regulatory processes. Notable examples include bicalutamide
for advanced prostate cancer, imatinib for chronic myeloid
leukaemia, anastrozole and letrozole as adjuvant treatment for
postmenopausal hormone receptor positive breast cancer,38 and
antiviral medicines for HIV/AIDS (including darunavir,
raltegravir, and etravirine).39 40
However, failure to register or fund a drug does not necessarily
mean the regulatory or reimbursement systems are cumbersome
or unfair.41 There may be too much uncertainty about a drug’s
safety or efficacy, or it may have low cost effectiveness or be
unaffordable.
Evidence is growing that accelerated approval of medicines
may cause serious harm. For example, medicines approved since
the US accelerated approval pathway was introduced are more
likely to be withdrawn from the market or receive a new “black
box warning” than those approved before its introduction.42
Similarly, drugs approved in Canada using its notice of
compliance with conditions pathway are more likely to have a
serious safety warning compared with those approved through
a standard review process.22
Medicines made available via accelerated approval mechanisms
may also prove to be ineffective. The independent drug bulletin
Prescrire assessed all 22 drugs that had been granted conditional
approval in the European Union since 2006, finding that less
than 40% of these offered an advantage over current therapies,
and there were insufficient data to make a judgment for nearly
a third.39 Similarly, most oncology drugs approved in the US
between 2008 and 2012 were approved on the basis of surrogate
endpoints, and further follow-up showed that more than half of
these had no or unknown effects on overall survival.43 Some,
such as such as bevacizumab (Avastin) for breast cancer44 and
gemtuzumab ozogamicin (Mylotarg) for chronic myeloid
leukaemia45 also had serious side effects and were withdrawn
from the market.
Although identifying more suitable surrogate endpoints could
reduce these problems, we believe that negotiating lower
evidence standards, whether in terms of endpoints or
experimental design, to accelerate access to medicines can
expose patients to futile treatments that, at best, provide false
hope and, at worst, cause serious harm.
Changes to reimbursement systems that involve disregarding
usual cost effectiveness thresholds for the subsidy of medicines
also have serious consequences for healthcare systems by
creating opportunity costs and overwhelming budgets. The
recent changes to the UK Cancer Drugs Fund are a case in point.
After the fund exceeded its budget by 50% in 2014,46 and
without assessment of the effect of the resources spent, in 2016
it was converted to a managed access programme that will
provide funding for therapies for two years while further data
are gathered.47 More permissive cost effectiveness thresholds
may increase not only overall expenditure but also the prices
of medicines. In 2004, a report commissioned by the US
Congress concluded that removing price controls (which
includes cost effectiveness analysis) would greatly increase
revenues from patented medicines—by, for example, almost
60% in Australia and more than 30% in the UK.48
Countering the rhetoric
Speeding up access to medicines is clearly appropriate and
beneficial in some cases. The problem is that the rhetoric
surrounding accelerated access makes it difficult to assess the
necessity and feasibility of such programmes. Combating this
rhetoric will not be easy, as it is natural for researchers to want
to promote their work to improve their status and chances of
receiving lucrative research grants; for manufacturers to promote
their product to increase their market share (and therefore the
return on investment for shareholders); and for media outlets
to tell emotive stories to sell papers. However, the following
steps would go some way to controlling it:
• Ensuring that press releases of research groups make factual
claims that do not overstate the evidence (this could be a
responsibility of institutions such as universities that oversee
research)
• Extending or more strictly enforcing regulations prohibiting
the promotion of off-label medications by pharmaceutical
companies
• Encouraging media outlets to report on both positive and
negative trial outcomes and not to set unrealistic expectations
when reporting the latest research through, for example the
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introduction of media standards for the results of drug trials
and provision of alternative messages such as the importance
of social solidarity and preventing the exploitation of
vulnerable patients by researchers, politicians and members
of the pharmaceutical industry.
Better response
It would be unrealistic, however, to believe that such strategies
could ever fully stop the calls for greater access to medicines,
which are underpinned by compassion and valid concerns such
as inequities for people with rare diseases and promotion of
biomedical innovation.35-49 We therefore have to find different
ways to respond. Perhaps the most obvious
alternative—although it is often neglected—is to increase
support for publicly funded clinical trials. Such trials,
particularly if they allow for crossover and open label
extensions, would provide patients with timely access to new
therapies (without the public misconstruing them as proved
therapies, which official regulatory and payer endorsements
tend to imply). They would also protect patients from harm by
providing adequate monitoring of both safety and efficacy and
allow for further data collection before therapies are used more
widely.
Although increasing publicly funded trials would demand
substantial investment, experience from paediatric oncology
shows that it is both feasible and can have groundbreaking
results. Many cancer treatments are licensed only for adults,50
but most children receive access through clinical trials. This
has been credited with increasing the overall five year survival
rate for childhood and adolescent cancers from about 60% in
the late 1970s to more than 80% today.51
Another approach could be to use drug pricing as a lever for
promoting access to medicines. Linking prices to demonstrable
evidence of effectiveness could allow for lower cost
effectiveness thresholds for drugs with the highest evidence and
would encourage companies to conduct high quality research
to improve their revenues, even after the medicine is on the
market. More ambitious pharmaceutical price reform strategies
would also increase access to medicines, although they are likely
to be strongly resisted by industry.
We cannot simply reject calls for accelerated access as the values
that underpin these calls are genuine and deeply felt. But
accelerated access programmes are not the best way of
respecting these values. Approaches to facilitating access to
medicines need to be based less on rhetoric and more on reason,
and need to remain cognisant of both the importance of
maintaining standards of safety, efficacy, and cost effectiveness
and the realities of finite health budgets.
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